{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:06:49Z","timestamp":1783980409937,"version":"3.55.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40257-021-00648-x","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T10:02:53Z","timestamp":1635933773000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identifying and Treating Ocular Manifestations in Psoriasis"],"prefix":"10.1007","volume":"23","author":[{"given":"Mahsaw","family":"Motlagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fortenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-0638","authenticated-orcid":false,"given":"Bobeck S.","family":"Modjtahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"issue":"19","key":"648_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"3","key":"648_CR2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"648_CR3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/jid.2012.434","volume":"133","author":"M Enamandram","year":"2013","unstructured":"Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):287\u20139.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"648_CR4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"648_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"648_CR6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jaad.2020.11.039","volume":"84","author":"J Burshtein","year":"2021","unstructured":"Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"9997","key":"648_CR7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"9583","key":"648_CR8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263\u201371.","journal-title":"Lancet"},{"issue":"12","key":"648_CR9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1346-8138.2007.00390.x","volume":"34","author":"NS Chandran","year":"2007","unstructured":"Chandran NS, et al. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol. 2007;34(12):805\u201310.","journal-title":"J Dermatol"},{"issue":"3","key":"648_CR10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5935\/0004-2749.20180044","volume":"81","author":"N Cruz","year":"2018","unstructured":"Cruz N, et al. Ocular manifestations of psoriasis. Arq Bras Oftalmol. 2018;81(3):219\u201325.","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"648_CR11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/09273948.2017.1414271","volume":"27","author":"S Abbagani","year":"2019","unstructured":"Abbagani S, Kamath YS, Nayak S. A study on ocular morbidity among patients with psoriasis visiting a Tertiary Care Hospital in Karnataka, Southern India. Ocul Immunol Inflamm. 2019;27(4):531\u20134.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"648_CR12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaad.2010.10.032","volume":"65","author":"B Rehal","year":"2011","unstructured":"Rehal B, et al. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"648_CR13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clindermatol.2015.11.014","volume":"34","author":"GF Webster","year":"2016","unstructured":"Webster GF, Durrani K, Suchecki J. Ocular rosacea, psoriasis, and lichen planus. Clin Dermatol. 2016;34(2):146\u201350.","journal-title":"Clin Dermatol"},{"issue":"1","key":"648_CR14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/ICL.0000000000000178","volume":"43","author":"M Gonzalez-Andrades","year":"2017","unstructured":"Gonzalez-Andrades M, et al. Sterile corneal infiltrates secondary to psoriasis exacerbations: topical tacrolimus as an alternative treatment option. Eye Contact Lens. 2017;43(1):e1\u20133.","journal-title":"Eye Contact Lens"},{"issue":"3","key":"648_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0733-8635(18)30321-8","volume":"10","author":"PC Donshik","year":"1992","unstructured":"Donshik PC, Hoss DM, Ehlers WH. Inflammatory and papulosquamous disorders of the skin and eye. Dermatol Clin. 1992;10(3):533\u201347.","journal-title":"Dermatol Clin"},{"issue":"12","key":"648_CR16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bjo.54.12.810","volume":"54","author":"P Eustace","year":"1970","unstructured":"Eustace P, Pierse D. Ocular psoriasis. Br J Ophthalmol. 1970;54(12):810\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"648_CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000249009","volume":"174","author":"JD Bernhard","year":"1987","unstructured":"Bernhard JD. Is eyelid involvement a sign of severe psoriasis? Dermatologica. 1987;174(3):151.","journal-title":"Dermatologica"},{"issue":"3","key":"648_CR18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2230.2001.00814.x","volume":"26","author":"R Ajitsaria","year":"2001","unstructured":"Ajitsaria R, et al. Psoriasis, psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol. 2001;26(3):274\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"648_CR19","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jcjo.2012.04.005","volume":"47","author":"I Ssi-Yan-Kai","year":"2012","unstructured":"Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol. 2012;47(6):e42\u20133.","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"648_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-4632.2011.05424.x","volume":"52","author":"B Kilic","year":"2013","unstructured":"Kilic B, et al. Ocular findings in patients with psoriasis. Int J Dermatol. 2013;52(5):554\u20139.","journal-title":"Int J Dermatol"},{"issue":"4","key":"648_CR21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0420.1996.tb00708.x","volume":"74","author":"N Zengin","year":"1996","unstructured":"Zengin N, et al. Tear film and meibomian gland functions in psoriasis. Acta Ophthalmol Scand. 1996;74(4):358\u201360.","journal-title":"Acta Ophthalmol Scand"},{"issue":"4","key":"648_CR22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10384-012-0226-4","volume":"57","author":"Y Her","year":"2013","unstructured":"Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol. 2013;57(4):341\u20136.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"648_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/bjophthalmol-2017-310307","volume":"102","author":"E Aragona","year":"2018","unstructured":"Aragona E, et al. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol. 2018;102(3):302\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"648_CR24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00003226-199909000-00005","volume":"18","author":"AA Karabulut","year":"1999","unstructured":"Karabulut AA, et al. Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea. 1999;18(5):544\u20138.","journal-title":"Cornea"},{"issue":"1","key":"648_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5935\/0004-2749.20170002","volume":"80","author":"G Demirci","year":"2017","unstructured":"Demirci G, et al. Tear osmolarity and ocular surface parameters in patients with psoriasis. Arq Bras Oftalmol. 2017;80(1):1\u20133.","journal-title":"Arq Bras Oftalmol"},{"issue":"3","key":"648_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","volume":"16","author":"N Huynh","year":"2008","unstructured":"Huynh N, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008;16(3):89\u201393.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"648_CR27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0536.2006.00927.x","volume":"55","author":"KA Amin","year":"2006","unstructured":"Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis. 2006;55(5):280\u20135.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"648_CR28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.clindermatol.2019.07.029","volume":"37","author":"Z Demerdjieva","year":"2019","unstructured":"Demerdjieva Z, Mazhdrakova I, Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol. 2019;37(6):663\u20137.","journal-title":"Clin Dermatol"},{"issue":"6","key":"648_CR29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2340\/0001555564557559","volume":"64","author":"A Catsarou-Catsari","year":"1984","unstructured":"Catsarou-Catsari A, et al. Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol. 1984;64(6):557\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"648_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000301255","volume":"124","author":"F Vrabec","year":"1952","unstructured":"Vrabec F. Histologic description of a case of psoriasis with conjunctival, corneal and cutaneous localization. Ophthalmologica. 1952;124(2):105\u20138 (In undetermined language).","journal-title":"Ophthalmologica"},{"issue":"3","key":"648_CR31","doi-asserted-by":"crossref","first-page":"Np7","DOI":"10.1177\/1120672118823121","volume":"30","author":"R Amer","year":"2020","unstructured":"Amer R, Levinger N. Psoriasis-associated progressive necrotizing posterior scleritis: a 6-year follow-up. Eur J Ophthalmol. 2020;30(3):Np7\u201310.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"648_CR32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/09273948.2014.896467","volume":"23","author":"RC Stacy","year":"2015","unstructured":"Stacy RC, et al. Posterior necrotizing scleritis presenting as sectoral chorioretinitis. Ocul Immunol Inflamm. 2015;23(5):412\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"648_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00006982-200310000-00022","volume":"23","author":"R Altan-Yaycioglu","year":"2003","unstructured":"Altan-Yaycioglu R, et al. Posterior scleritis in psoriatic arthritis. Retina. 2003;23(5):717\u20139.","journal-title":"Retina"},{"issue":"6264","key":"648_CR34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/bmj.282.6264.609-a","volume":"282","author":"JM Boss","year":"1981","unstructured":"Boss JM, et al. Peripheral corneal melting syndrome in association with psoriasis: a report of two cases. Br Med J (Clin Res Ed). 1981;282(6264):609\u201310.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"648_CR35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0002-9394(14)72790-4","volume":"119","author":"K Moadel","year":"1995","unstructured":"Moadel K, et al. Psoriatic corneal abscess. Am J Ophthalmol. 1995;119(6):800\u20131.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"648_CR36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bjd.12686","volume":"170","author":"VG Herbert","year":"2014","unstructured":"Herbert VG, et al. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease. Br J Dermatol. 2014;170(3):746\u20138.","journal-title":"Br J Dermatol"},{"issue":"12","key":"648_CR37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00347-014-3115-z","volume":"111","author":"FS Filev","year":"2014","unstructured":"Filev FS, et al. Psoriasis-associated keratitis: case report. Ophthalmologe. 2014;111(12):1201\u20133 (In German).","journal-title":"Ophthalmologe"},{"issue":"9","key":"648_CR38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/01.ico.0000244874.85255.7c","volume":"25","author":"BH Jeng","year":"2006","unstructured":"Jeng BH, Downs-Kelly E, Langston RH. Superficial hypertrophic dendritic epitheliopathy occurring before and after penetrating keratoplasty in a patient with psoriasis. Cornea. 2006;25(9):1097\u20139.","journal-title":"Cornea"},{"issue":"4","key":"648_CR39","first-page":"173","volume":"19","author":"G Lafond","year":"1984","unstructured":"Lafond G, Roy PE, Grenier R. Lens opacities appearing during therapy with methoxsalen and long-wavelength ultraviolet radiation. Can J Ophthalmol. 1984;19(4):173\u20135.","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"648_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.1993.tb00834.x","volume":"34","author":"JA See","year":"1993","unstructured":"See JA, Weller P. Ocular complications of PUVA therapy. Australas J Dermatol. 1993;34(1):1\u20134.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"648_CR41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clindermatol.2014.10.017","volume":"33","author":"J DePry","year":"2015","unstructured":"DePry J, et al. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247\u201355.","journal-title":"Clin Dermatol"},{"issue":"2","key":"648_CR42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaad.2007.04.027","volume":"57","author":"D Malanos","year":"2007","unstructured":"Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"648_CR43","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archderm.1985.01660100087021","volume":"121","author":"TY Woo","year":"1985","unstructured":"Woo TY, et al. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. Arch Dermatol. 1985;121(10):1307\u20138.","journal-title":"Arch Dermatol"},{"issue":"3","key":"648_CR44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"648_CR45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/S0365-05962012000600009","volume":"87","author":"NA Fraga","year":"2012","unstructured":"Fraga NA, et al. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87(6):877\u201383.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"648_CR46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2004.08.053","volume":"139","author":"K Durrani","year":"2005","unstructured":"Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139(1):106\u201311.","journal-title":"Am J Ophthalmol"},{"key":"648_CR47","first-page":"210","volume":"77","author":"DL Knox","year":"1979","unstructured":"Knox DL. Psoriasis and intraocular inflammation. Trans Am Ophthalmol Soc. 1979;77:210\u201324.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"648_CR48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.35.4.354","volume":"35","author":"JR Lambert","year":"1976","unstructured":"Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35(4):354\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"648_CR49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","volume":"135","author":"CC Chi","year":"2017","unstructured":"Chi CC, et al. Risk of uveitis among people with psoriasis: a Nationwide Cohort Study. JAMA Ophthalmol. 2017;135(5):415\u201322.","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"648_CR50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","volume":"32","author":"A Abbouda","year":"2017","unstructured":"Abbouda A, et al. Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol. 2017;32(6):715\u201320.","journal-title":"Semin Ophthalmol."},{"issue":"6","key":"648_CR51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/1203475420952420","volume":"24","author":"M Lam","year":"2020","unstructured":"Lam M, et al. The incidence and prevalence of uveitis in psoriasis: a systematic review and meta-analysis. J Cutan Med Surg. 2020;24(6):601\u20137.","journal-title":"J Cutan Med Surg"},{"issue":"11","key":"648_CR52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamadermatol.2015.1986","volume":"151","author":"A Egeberg","year":"2015","unstructured":"Egeberg A, et al. Association of psoriatic disease with uveitis: a Danish Nationwide Cohort Study. JAMA Dermatol. 2015;151(11):1200\u20135.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"648_CR53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0021-5155(00)00359-2","volume":"45","author":"F Okamoto","year":"2001","unstructured":"Okamoto F, et al. Factors associated with increased aqueous flare in psoriasis. Jpn J Ophthalmol. 2001;45(2):172\u20136.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"648_CR54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/ced.13916","volume":"44","author":"HH Oon","year":"2019","unstructured":"Oon HH, et al. Acute unilateral red eye in a patient with psoriasis. Clin Exp Dermatol. 2019;44(8):924\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"648_CR55","first-page":"91","volume":"9","author":"C Fotiadou","year":"2019","unstructured":"Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks. Psoriasis (Auckl). 2019;9:91\u20136.","journal-title":"Psoriasis (Auckl)."},{"issue":"6","key":"648_CR56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/09273948.2011.624287","volume":"19","author":"NE Abu-Yaghi","year":"2011","unstructured":"Abu-Yaghi NE, et al. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011;19(6):426\u201330.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"648_CR57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000247225","volume":"187","author":"S Hesse","year":"1993","unstructured":"Hesse S, et al. Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids. Dermatology. 1993;187(2):137\u20139.","journal-title":"Dermatology"},{"issue":"3","key":"648_CR58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/ICU.0000000000000466","volume":"29","author":"JE Weinstein","year":"2018","unstructured":"Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol. 2018;29(3):267\u201374.","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"648_CR59","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/1346-8138.16062","volume":"48","author":"YX Dai","year":"2021","unstructured":"Dai YX, et al. Risk of retinal diseases in patients with psoriasis: a population-based cohort study in Taiwan. J Dermatol. 2021;48(10):1550\u20136.","journal-title":"J Dermatol"},{"key":"648_CR60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fnins.2021.629401","volume":"15","author":"N Castellino","year":"2021","unstructured":"Castellino N, et al. Retinal vascular assessment in psoriasis: a multicenter study. Front Neurosci. 2021;15:30.","journal-title":"Front Neurosci"},{"key":"648_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.067","author":"CW Enos","year":"2019","unstructured":"Enos CW, et al. Peripheral retinal vascular leakage in moderate to severe psoriasis: a pilot study. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.067 (Epub 28 May 2019).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"648_CR62","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13904","volume":"75","author":"M Aksoy","year":"2021","unstructured":"Aksoy M, Toptan M, An I. Retinal nerve fiber layer thickness and choroidal thickness: an evaluation in psoriasis patients. Int J Clin Pract. 2021;75(4): e13904.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"648_CR63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/09273948.2016.1150493","volume":"25","author":"I Ersan","year":"2017","unstructured":"Ersan I, et al. Evaluation of macular ganglion cell-inner plexiform layer and choroid in psoriasis patients using enhanced depth imaging spectral domain optical coherence tomography. Ocul Immunol Inflamm. 2017;25(4):520\u20134.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"648_CR64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10792-016-0252-1","volume":"37","author":"R K\u0131l\u0131\u00e7","year":"2017","unstructured":"K\u0131l\u0131\u00e7 R, et al. Choroidal thickness in psoriasis. Int Ophthalmol. 2017;37(1):173\u20137.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"648_CR65","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2015.03.002","volume":"72","author":"LT Kao","year":"2015","unstructured":"Kao LT, et al. Association between psoriasis and neovascular age-related macular degeneration: a population-based study. J Am Acad Dermatol. 2015;72(6):1090\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"648_CR66","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1097\/IAE.0000000000000536","volume":"35","author":"YC Yen","year":"2015","unstructured":"Yen YC, et al. Risk of retinal vein occlusion in patients with psoriasis: a population-based cohort study. Retina. 2015;35(9):1786\u201394.","journal-title":"Retina"},{"issue":"1","key":"648_CR67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/09546634.2019.1577947","volume":"31","author":"F Ghalamkarpour","year":"2020","unstructured":"Ghalamkarpour F, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatolog Treat. 2020;31(1):27\u201332.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"648_CR68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","volume":"10","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11.","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"5","key":"648_CR69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(81)80047-3","volume":"5","author":"DL Cram","year":"1981","unstructured":"Cram DL. Corneal melting in psoriasis. J Am Acad Dermatol. 1981;5(5):617.","journal-title":"J Am Acad Dermatol"},{"issue":"3 Suppl","key":"648_CR70","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/IOP.0000000000001781","volume":"37","author":"FT Fraunfelder","year":"2021","unstructured":"Fraunfelder FT, Fraunfelder FW. Possible association between apremilast therapy and increased tearing. Ophthalmic Plast Reconstr Surg. 2021;37(3 Suppl):S31\u20132.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"7","key":"648_CR71","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ophtha.2003.12.052","volume":"111","author":"FW Fraunfelder","year":"2004","unstructured":"Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275\u20139.","journal-title":"Ophthalmology"},{"issue":"3","key":"648_CR72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9394(01)01024-8","volume":"132","author":"FT Fraunfelder","year":"2001","unstructured":"Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299\u2013305.","journal-title":"Am J Ophthalmol"},{"issue":"1 Pt 2","key":"648_CR73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0190-9622(88)70166-8","volume":"19","author":"MA Lebowitz","year":"1988","unstructured":"Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol. 1988;19(1 Pt 2):209\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"648_CR74","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/archopht.122.6.928","volume":"122","author":"N Lois","year":"2004","unstructured":"Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122(6):928\u201330.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"648_CR75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","volume":"13","author":"KC LaMattina","year":"2017","unstructured":"LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181\u20138.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"648_CR76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/09273948.2011.644383","volume":"20","author":"ET Cunningham Jr","year":"2012","unstructured":"Cunningham ET Jr, et al. Drug-induced inflammation in patients on TNF\u03b1 inhibitors. Ocul Immunol Inflamm. 2012;20(1):2\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"648_CR77","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.mayocp.2014.08.012","volume":"89","author":"G Damento","year":"2014","unstructured":"Damento G, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-\u03b1 inhibitors. Mayo Clin Proc. 2014;89(11):1481\u20136.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"648_CR78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/09273972.2014.999796","volume":"23","author":"J Drury","year":"2015","unstructured":"Drury J, Hickman SJ. Internuclear ophthalmoplegia associated with anti-TNF\u03b1 medication. Strabismus. 2015;23(1):30\u20132.","journal-title":"Strabismus"},{"issue":"8","key":"648_CR79","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/02713683.2010.486520","volume":"35","author":"V Kakkassery","year":"2010","unstructured":"Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35(8):751\u20136.","journal-title":"Curr Eye Res"},{"issue":"6","key":"648_CR80","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1111\/aos.13699","volume":"96","author":"I Leal","year":"2018","unstructured":"Leal I, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis\u2014a systematic review. Acta Ophthalmol. 2018;96(6):e665\u201375.","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"648_CR81","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A Registry-Based Study. Arthritis Rheum. 2007;56(10):3248\u201352.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"648_CR82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/112067210601600225","volume":"16","author":"JA Montero","year":"2006","unstructured":"Montero JA, et al. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol. 2006;16(2):343\u20135.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"648_CR83","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, et al. Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868\u201374.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"648_CR84","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00417-009-1065-y","volume":"247","author":"M Tsilimbaris","year":"2009","unstructured":"Tsilimbaris M, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1119\u201325.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"648_CR85","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","volume":"30","author":"D Wendling","year":"2014","unstructured":"Wendling D, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"648_CR86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling D, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503\u201310.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"648_CR87","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","volume":"155","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155(1):183-189.e1.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"648_CR88","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.eye.6703100","volume":"22","author":"P Arriola-Villalobos","year":"2008","unstructured":"Arriola-Villalobos P, et al. Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye (Lond). 2008;22(4):599\u2013600.","journal-title":"Eye (Lond)"},{"issue":"2","key":"648_CR89","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2014.993024","volume":"31","author":"P Brito-Zer\u00f3n","year":"2015","unstructured":"Brito-Zer\u00f3n P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31(2):251\u20132.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"648_CR90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233\u20139.","journal-title":"J Rheumatol"},{"issue":"2","key":"648_CR91","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cxo.12904","volume":"103","author":"T Kowalski","year":"2020","unstructured":"Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom. 2020;103(2):148\u201354.","journal-title":"Clin Exp Optom"},{"issue":"7","key":"648_CR92","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/ICO.0000000000000465","volume":"34","author":"VP Lezcano Carduz","year":"2015","unstructured":"Lezcano Carduz VP, Mingo Bot\u00edn D, Dur\u00e1n Poveda SP. Squamous cell neoplasm of the ocular surface in a patient with psoriasis treated with tumor necrosis factor-alpha inhibitors. Cornea. 2015;34(7):833\u20134.","journal-title":"Cornea"},{"key":"648_CR93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12886-015-0047-6","volume":"15","author":"A Matet","year":"2015","unstructured":"Matet A, et al. Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol. 2015;15:57.","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"648_CR94","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1345\/aph.1G279","volume":"39","author":"R Noguera-Pons","year":"2005","unstructured":"Noguera-Pons R, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005;39(12):2131\u20135.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"648_CR95","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","volume":"14","author":"M Taban","year":"2006","unstructured":"Taban M, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145\u201350.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"648_CR96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaapos.2005.12.002","volume":"10","author":"T Tauber","year":"2006","unstructured":"Tauber T, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26\u20139.","journal-title":"J AAPOS"},{"key":"648_CR97","doi-asserted-by":"crossref","unstructured":"Yokoyama W, Takada K, Miyasaka N, Kohsaka H. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. 2014 Aug 1; 2014:bcr-2014-205779.","DOI":"10.1136\/bcr-2014-205779"},{"issue":"5","key":"648_CR98","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.122.5.793","volume":"122","author":"LJ Mejico","year":"2004","unstructured":"Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"648_CR99","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaophthalmol.2018.5413","volume":"137","author":"HMT Teo","year":"2019","unstructured":"Teo HMT, de S\u00e1 FF, Demirci H. Association of blepharitis and ectropion with tumor necrosis factor \u03b1 inhibitor treatment in crohn disease. JAMA Ophthalmol. 2019;137(2):232\u20133.","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"648_CR100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10792-017-0532-4","volume":"38","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, et al. Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy. Int Ophthalmol. 2018;38(2):841\u20137.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"648_CR101","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00417-008-0765-z","volume":"246","author":"RP Manzano","year":"2008","unstructured":"Manzano RP, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):907\u201311.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"648_CR102","volume":"5","author":"CMC Becerra","year":"2020","unstructured":"Becerra CMC, et al. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1): e000331.","journal-title":"BMJ Open Ophthalmol."},{"issue":"1","key":"648_CR103","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12886-018-0832-0","volume":"18","author":"WK Song","year":"2018","unstructured":"Song WK, Cho AR, Yoon YH. Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. BMC Ophthalmol. 2018;18(1):156.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"648_CR104","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/09273948.2019.1569245","volume":"28","author":"AS Thomas","year":"2020","unstructured":"Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491\u20133.","journal-title":"Ocul Immunol Inflamm"},{"key":"648_CR105","doi-asserted-by":"crossref","unstructured":"Martinez CE, Allen JB, Davidorf FH, Cebulla CM. Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Rep. 2017 Jun 29; 2017:bcr2017219296.","DOI":"10.1136\/bcr-2017-219296"},{"issue":"6","key":"648_CR106","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/ced.14198","volume":"45","author":"S Javadzadeh","year":"2020","unstructured":"Javadzadeh S, et al. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol. 2020;45(6):802\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"648_CR107","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/jcm10051031","volume":"10","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, et al. Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.","journal-title":"J Clin Med"},{"issue":"5","key":"648_CR108","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/aos.12515","volume":"93","author":"A Grzybowski","year":"2015","unstructured":"Grzybowski A, et al. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402\u201310.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"648_CR109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12348-011-0058-2","volume":"2","author":"A Kim","year":"2012","unstructured":"Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. 2012;2(3):145\u20137.","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"1","key":"648_CR110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000461572","volume":"9","author":"N Saffra","year":"2017","unstructured":"Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol. 2017;9(1):60\u20134.","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"648_CR111","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/ICB.0000000000000499","volume":"12","author":"SA Schechet","year":"2018","unstructured":"Schechet SA, et al. Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep. 2018;12(4):307\u20139.","journal-title":"Retin Cases Brief Rep."},{"issue":"12","key":"648_CR112","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-236041","volume":"13","author":"A Dermawan","year":"2020","unstructured":"Dermawan A, et al. Infliximab-induced optic neuritis. BMJ Case Rep. 2020;13(12): e236041.","journal-title":"BMJ Case Rep"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00648-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00648-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00648-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T06:00:27Z","timestamp":1699768827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00648-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00648-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"6 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mahsaw Motlagh, Christopher Fortenbach, and Howard I. Maibach have no conflicts of interest to declare. Bobeck S. Modjtahedi has received research support from Genentech outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not required for this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Figures 1 and 3 were reprinted from Rehal et al. [], with permission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"MM literature search, analysis, and manuscript draft; CF literature search, analysis, and manuscript draft; HIM manuscript draft and critical revisions; BSM study conception, manuscript draft, and critical revisions. All authors reviewed and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}